Open Nav

Thomas Krol

Chief Development Officer

Axolo Pharma

Dr Krol is currently Chief Development Officer of Axolo Pharma, a JV to develop and commercialize injetable MG53. Tom was previously Managing Director at the Kansas Bioscience Authority (KBA), a $580 million fund created by the state of Kansas, where he led human health investment activities.

Tom has more than 25 years of biopharma experience spanning multiple roles in R&D, technology assessment, marketing, L&BD for bigpharma and start-up pharma. Tom had multiple roles at Oakwood Labs, Verenta Pharmaceuticals, CyDex- Ligand, Pharmacia-Pfizer, Searle, Sanofi-Aventis and predecessor companies, including Marion Laboratories.

This speaker's sessions: